Warfarin individual anticoagulant pharmacogenomics detection kit suitable for Chinese population

Abstract

The invention provides a warfarin individual anticoagulant pharmacogenomics detection kit suitable for Chinese population, which mainly comprises CYP2C9, VKORC1 and CYP4F2 related gene-type amplification primers, CYP2C9, VKORC1 and CYP4F2 related gene-type sequencing primers, a polymerase chain reaction (PCR) reagent and a sequencing reagent. The warfarin individual anticoagulant pharmacogenomicsdetection kit suitable for the Chinese population also can comprise a specification used for explaining a warfarin pharmacogenomics dose prediction model suitable for the Chinese population or / and a computer readable storage medium recording the warfarin pharmacogenomics dose prediction model suitable for the Chinese population. The warfarin pharmacogenomics detection kit provided by the invention is simple in preparation and is convenient in use. By adopting the kit, the warfarin anticoagulant therapy dose of Chinese patient population can be accurately estimated through detecting warfarin pharmacogenomics indexes, integrating clinical environmental factors and utilizing warfarin pharmacogenomics dose prediction model software suitable for the Chinese population, which is established by the invention.

Description

technical field [0001] The invention relates to a kit, in particular to a pharmacogenomics detection kit suitable for individualized anticoagulation of warfarin in Chinese population. Background technique [0002] Warfarin is the most commonly used and most widely used effective oral anticoagulant drug in clinical practice. However, due to the narrow therapeutic window, the therapeutic dose varies significantly among individuals. There is a possibility of serious bleeding side effects, and insufficient dose will lead to the risk of thromboembolism due to insufficient anticoagulation. Therefore, the individualization of warfarin anticoagulant therapy has always been the focus and difficulty in clinical work. [0003] In recent years, more and more evidences have shown that in addition to clinical environmental factors (such as age, body weight, intake of vitamin K in the diet, anticoagulant indications, concomitant medications, etc.), the genetic variation of the genome large...

AI Technical Summary

Problems solved by technology

[0002] Warfarin is the most commonly used and most widely used effective oral anticoagulant drug in clinical practice. However, due to the narrow therapeutic window, the therapeutic dose varies significantly among individuals. There is a possibility of serious bleeding side effects, and insufficient dosage will lead to the risk of thromboembolism due to insufficient anticoagulation. Therefore, the individualization of warfarin anticoagulation therapy has always been the focus and difficulty in clinical work.

[0005] Nevertheless, most of the published warfarin pharmacogenomics dose prediction models are based on multi-ethnic populations or Western populations, although the dose differences caused by ethnic differences can be reflected in the genetic variants in the prediction models, For example: the genetic variant VKORC1 (-1639A) associated with low doses of warfarin occurs more frequently in Asian populations (approximately 87%) than in Western populations (approximately 36%), but needs to be integrated in the model Clinical environment factors are different in different ethnic groups. In addition, the predicted dose calculated by using the published pharmacogenomic model based on multi-ethnic or Western population is often higher than the actual required dose of the Chinese population.

Images